Cite
MLA Citation
Chie-Schin Shih et al.. “NFM-01. NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY.” Neuro-oncology, vol. 20, no. 2, n.d., p. i142. http://access.bl.uk/ark:/81055/vdc_100095475785.0x000018